Loading...
•
Sep 30, 2020
Amphastar Q3 2020 Earnings Report
Reported net revenues of $83.4 million and GAAP net income of $3.9 million for the three months ended September 30, 2020.
Key Takeaways
Amphastar Pharmaceuticals reported a 4% increase in net revenues to $83.4 million for the third quarter of 2020, driven by the continued strength of Primatene Mist and the re-launch of their epinephrine vial product. GAAP net income was $3.9 million, or $0.08 per share, while adjusted non-GAAP net income was $7.6 million, or $0.15 per share.
Net revenues for Q3 2020 were $83.4 million.
GAAP net income for Q3 2020 was $3.9 million, or $0.08 per share.
Adjusted non-GAAP net income for Q3 2020 was $7.6 million, or $0.15 per share.
Growth was driven by Primatene Mist and the re-launch of the epinephrine vial product.
Revenue by Segment
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...